Regeneron Pharmaceuticals

This study tests a new gene therapy called DB-OTO for children born with hearing loss because of changes in the otoferlin gene. The treatment is injected into the inner ear and aims to restore hearing. Up to 30 children and infants will take part to check if it is safe and works …

This study tests an experimental drug called REGN7999 in people with a form of beta-thalassemia that does not require regular blood transfusions. The drug is given as a shot under the skin and aims to safely reduce the extra iron that builds up in the body. About 95 adults will t…

This study tests whether adding an experimental drug (fianlimab) to a standard immunotherapy (cemiplimab) works better than the standard drug alone for people with head and neck cancer that has returned or spread. About 120 adults whose tumors show a specific protein (PD-L1) will…

This study tests a new two-drug combination (fianlimab and cemiplimab) against an already approved combination (relatlimab and nivolumab, sold as Opdualag) in people with advanced melanoma that cannot be removed by surgery or has spread. The goal is to see if the new combo is saf…

This study tests a new drug called REGN5093 in people with advanced non-small cell lung cancer that has a specific change in the MET gene. The first part finds a safe dose, and the second part checks if the drug can shrink tumors. About 231 adults will take part.

This study tests two experimental drugs, pozelimab and cemdisiran, in 35 adults with paroxysmal nocturnal hemoglobinuria (PNH) whose disease is still active despite standard C5 inhibitor therapy. The goal is to see if the combination can better control red blood cell destruction …

This study tests an experimental drug called mibavademab in people with a rare type of obesity caused by a faulty leptin gene. The gene change stops the body from feeling full, leading to severe weight gain. The drug aims to replace the missing signal and help control weight. Onl…

This study tests an experimental drug called marlotamig (REGN7075) alone or with cemiplimab (with or without chemo) in people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors or slow cancer growth. About 933 participants…

This study tests an experimental drug called ALN-SOD in people with ALS caused by a specific gene change (SOD1 mutation). The main goal is to check safety and how well the drug is tolerated. Researchers will also measure drug levels in blood and spinal fluid, and look at biomarke…

This study tests whether injecting the drug cemiplimab directly into early-stage skin cancer tumors can work as well as surgery to remove them. About 369 adults with a type of skin cancer called cutaneous squamous cell carcinoma will be randomly assigned to get either the injecti…

This study tests a new drug, linvoseltamab, in people with multiple myeloma that has returned or not responded to other treatments. The goal is to find the best dose and check if it is safe and can shrink the cancer. About 387 adults will take part in this early-phase trial.

This study tests a new drug, linvoseltamab, given alone or with another drug (carfilzomib) against standard treatments for people with multiple myeloma that has returned or stopped responding to prior therapy. About 915 adults who have had 1 to 3 prior treatments will take part. …

This study tests two experimental drugs, REGN4336 and REGN5678, in people with advanced prostate cancer that has spread and stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors. About 228 participants will take par…

This early-stage study tests an experimental drug, REGN10597, alone or with another drug (cemiplimab) in people with advanced solid tumors like melanoma and kidney cancer. The main goals are to check safety, find the right dose, and see if the drugs can shrink tumors. About 240 a…

This study tests an experimental drug for lupus nephritis, a kidney disease caused by lupus. The main goal is to see if the drug is safe and tolerable over the long term. About 90 people with hard-to-treat lupus nephritis will take part. The drug is given for a short time, but pa…

This study compares an experimental drug (odronextamab) plus chemotherapy against the current standard treatment (rituximab plus chemotherapy) for people with untreated diffuse large B-cell lymphoma. About 904 participants will be enrolled to see if the new combination works bett…

This study tests two experimental drugs, pozelimab and cemdisiran, alone or together, to see if they can slow the growth of blind spots (geographic atrophy) in people with advanced dry age-related macular degeneration. About 975 adults with moderate vision loss will receive injec…

This early-stage study tests an experimental treatment called 27T51, a type of immune cell therapy (CAR T) designed to target a protein called MUC16 found on certain cancer cells. The study involves about 90 women with ovarian, peritoneal, or fallopian tube cancer that has come b…

This study tests a new drug, mibavademab, in people with generalized lipodystrophy (GLD), a rare condition where the body lacks fat tissue, leading to serious metabolic problems. The goal is to see if the drug can improve blood sugar and fat levels safely. About 28 children and a…

This phase 3 study tests a new drug, linvoseltamab, against a standard three-drug combo (EPd) in people whose multiple myeloma has returned after 1-4 prior treatments. About 410 participants will be randomly assigned to receive either linvoseltamab or EPd. The goal is to see whic…

This study tests an experimental drug called ALN-SNCA in 46 people with early Parkinson's disease. The drug is given as a single injection into the spinal fluid to try to lower a harmful protein linked to Parkinson's. The main goal is to check if the drug is safe and tolerable, a…

This program provides expanded access to REGN4461 for people with lipodystrophy or monogenic obesity caused by a lack of leptin signaling. The goal is to help manage these rare conditions by replacing the missing leptin signal. Participants must have a confirmed diagnosis and no …

This early-stage study tests an experimental drug called pozelimab, given as an injection into the eye, for people with geographic atrophy (GA), a condition that damages the retina and causes vision loss. The main goal is to check the drug's safety and tolerability in 54 particip…

This early-stage study tests an experimental drug called ALN-PNP in healthy adults and people with a type of fatty liver disease (MASLD) who have a specific gene variant. The main goal is to check the drug's safety and how well the body tolerates it. Researchers will also measure…

This study tests a new drug, odronextamab, for people with untreated follicular lymphoma, a type of blood cancer. About 822 participants will receive either the new drug or standard treatment (rituximab plus chemotherapy) to compare safety and effectiveness. The goal is to see if…

This study tests if adding an extra cancer drug to the standard immunotherapy (cemiplimab) and chemotherapy helps shrink early-stage lung cancer more before surgery. About 120 adults with stage II-IIIB non-small cell lung cancer will be randomly assigned to receive either the two…

This study tests an experimental drug called mibavademab in 34 women with Functional Hypothalamic Amenorrhea (FHA), a condition where the brain doesn't send the right signals to the ovaries, causing missed periods. The goal is to see if the drug can help the body make hormones ne…

This study tests an experimental drug, linvoseltamab, in people with a rare disease called AL amyloidosis that has come back or not responded to other treatments. The drug aims to reduce abnormal proteins that damage organs like the heart and kidneys. About 220 participants will …

This study tests an experimental drug called ALN-CIDEB in adults with fatty liver disease (MASLD or MASH). The goal is to check safety and how well the drug reduces liver fat. About 132 participants will receive either the drug or a placebo. The study is currently recruiting.

This study tests an experimental gene therapy called REGV131-LNP1265 for people with severe or moderately severe hemophilia B. The therapy uses CRISPR to insert a working gene into DNA, aiming to teach the body to produce its own clotting factor and reduce the need for regular fa…

This study tests an experimental drug called linvoseltamab in people with newly diagnosed multiple myeloma. It aims to find the best dose and check if the drug is safe and can shrink tumors. About 149 participants will join, including those who can or cannot have a stem cell tran…

This early-phase trial tests an experimental drug called ubamatamab, alone or with another drug (cemiplimab), in people with ovarian or uterine cancer that has come back. The main goals are to check safety, find the best dose, and see if the treatment can shrink tumors. About 890…

This study tests a drug called vonsetamig in 56 people with chronic kidney disease who are on dialysis and have very high levels of antibodies that make it nearly impossible to find a matching kidney donor. The goal is to safely lower those antibodies so they can receive a kidney…

This study tests two experimental drugs, REGN7508 and REGN9933, in about 1,200 people with atrial fibrillation (an irregular heartbeat). The goal is to see if these drugs can prevent blood clots and strokes with less bleeding compared to the standard blood thinner apixaban. Parti…

This study tests two experimental drugs, ubamatamab and REGN7075, in 300 people with advanced non-small cell lung cancer that has spread. The goal is to see if the combination can shrink tumors and control the disease. A third drug, sarilumab, may be used to manage immune-related…

This study tests a new drug called olatorepatide in 120 adults who are overweight or obese but do not have diabetes. The goal is to see how safe the drug is, how the body processes it, and whether it helps with weight loss compared to a placebo. Participants will receive either t…

This study tests an investigational drug called linvoseltamab in 116 people with precancerous blood conditions (high-risk MGUS or non-high-risk smoldering multiple myeloma) that raise the risk of developing multiple myeloma. The goal is to see if the drug can eliminate abnormal p…

This study tests an investigational drug called REGN5668, alone or combined with other drugs, in people with ovarian, fallopian tube, primary peritoneal, or endometrial cancers. The goal is to find the safest dose and see if the treatment can shrink tumors. About 612 participants…

This study tests an experimental drug, dupilumab, in 20 children aged 6 months and older who have active eosinophilic esophagitis (EoE), a condition that causes swelling in the food pipe and makes eating difficult. The goal is to see if the drug is safe and works over 24 weeks. R…

This study tests an experimental drug called linvoseltamab combined with other cancer treatments for people with multiple myeloma that has come back after prior therapy. The main goal is to see if the combinations are safe and to find the right dose. About 317 adults with this bl…

This study tests an experimental drug, odronextamab, combined with lenalidomide in people whose follicular or marginal zone lymphoma has returned or not responded to prior treatment. The trial has two parts: first to find a safe dose, then to compare the new combo against the sta…

This program provides early access to ubamatamab for people with renal medullary carcinoma or epithelioid sarcoma who have no other treatment options. The drug aims to control these aggressive cancers. Eligibility is decided case by case.

This study tests an experimental drug called ALN-CFB in 24 people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cells despite standard treatment. The goal is to see if ALN-CFB is safe and tolerable compared to a placebo, and how it affects blood leve…

This study tests a new experimental drug, REGN7945, combined with another experimental drug, linvoseltamab, in people whose multiple myeloma has returned or not responded to at least three prior treatments. The goal is to see if the combination is safe and works better than linvo…

This early-stage study tests a new drug (REGN5837) combined with another drug (odronextamab) for people with aggressive B-cell lymphoma that has come back or not responded to at least two prior treatments. The first part finds a safe dose, and the second part checks how well the …

This study tests an experimental drug called REGN13335 for people with pulmonary arterial hypertension (PAH), a condition that makes it hard for the heart to pump blood to the lungs. About 99 adults with mild to moderate symptoms who are already on standard PAH medications will r…

This study tests a new drug, REGN5678, alone or with another drug (cemiplimab) in people with advanced prostate cancer that no longer responds to hormone therapy. The goal is to find safe doses and see if the drugs can shrink tumors by helping the immune system attack cancer cell…

This study tests a new drug, REGN17372, combined with another drug, linvoseltamab, in people whose multiple myeloma has returned or stopped responding to treatment. The goal is to find a safe dose and see if the combination shrinks tumors better than linvoseltamab alone. About 15…

This study tests a drug called pozelimab in 5 children aged 1 to 5 who have CHAPLE disease, a rare inherited condition causing severe stomach and heart problems. The main goal is to see if the drug is safe and to check how it affects the body. Researchers will also measure drug l…

This early-phase study tests an experimental drug, linvoseltamab, combined with dupilumab in 6 adults with severe food allergies (like peanut or milk) that can cause life-threatening reactions. The goal is to see if the combo is safe and how it affects IgE antibodies, which drive…

This study tests two experimental drugs (ALN-ANG3 and evinacumab) in about 270 adults with diabetic kidney disease. The goal is to see if they safely reduce protein in the urine and help preserve kidney function. Participants must have type 2 diabetes and moderate to severe kidne…

This study is for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. It tests the long-term safety and effectiveness of two experimental drugs, pozelimab and cemdisiran, taken together. About 202 participants will receive the combination therapy to see …

This study tests an experimental drug called ubamatamab, alone or with other cancer drugs, in people with advanced ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see how safe and effective these combinations are. About 220 participants w…

This study tests an experimental drug called ALN-HSD for people with MASH, a liver disease caused by fat buildup that leads to scarring and possible liver failure. The drug uses gene silencing to target the root cause and reduce liver fibrosis. About 120 adults with genetic risk …

This study tests an experimental drug called odronextamab for people with aggressive B-cell non-Hodgkin lymphoma whose cancer has returned or no longer responds to treatment. About 216 participants will receive either the new drug or standard therapy to compare safety, effectiven…

This program provides emergency access to an experimental antibody treatment (REGN-EB3) for people sick with Ebola virus disease in outbreak regions. It is for patients who are not eligible for or cannot join the main clinical trials. The goal is to control the viral infection an…

This program gives people with certain types of lymphoma (like follicular lymphoma or diffuse large B-cell lymphoma) who have tried all other treatments access to an experimental drug called odronextamab. The goal is to provide a possible treatment option when no others are avail…

This early-phase study tests a new imaging drug (89Zr-DFO-REGN5054) that may help doctors see immune cells inside tumors using PET scans. About 50 adults with advanced solid cancers who are also receiving the immunotherapy cemiplimab will take part. The main goal is to check safe…

This study tests an experimental drug called REGN7508 against aspirin to prevent dangerous blood clots after knee replacement surgery. About 2000 adults having a knee replaced will receive either REGN7508 or aspirin. The goal is to see which works better at stopping clots and is …

This study tests an experimental drug, REGN7508, to see if it can prevent dangerous blood clots in people with solid tumors who are receiving cancer treatment. About 860 participants will receive either the drug or a placebo. The goal is to find a safer way to reduce clot risk wi…

This study tests an experimental drug, REGN7508, to prevent dangerous blood clots in adults having knee replacement surgery. About 2000 participants will receive either REGN7508 or standard blood thinners (apixaban or enoxaparin). The goal is to see if the new drug works better a…

This study tests two experimental drugs (REGN5713 and REGN5715) given alone or together to reduce eye allergy symptoms caused by birch pollen. About 350 adults with birch pollen allergy will receive the drugs or a placebo and then be exposed to pollen in a controlled setting to m…

This study is a registry that will follow about 350 people with eosinophilic esophagitis (EoE) who are starting Dupixent as part of their normal treatment. Researchers want to see how the medicine is used in real life and how it affects symptoms, swallowing, and quality of life. …

This study follows about 50 people who have already received gene modified T cell therapy in a previous trial. Researchers will check for delayed side effects, see how long the modified cells last, and track disease status over time. Participants will have regular safety visits a…

This study follows 500 adults with advanced non-small cell lung cancer who are prescribed cemiplimab (Libtayo) as part of their normal care. Researchers will track how long patients live, how their tumors respond, and any side effects. The goal is to see how well the drug works i…

This study follows about 20 people with chronic kidney disease who already received the experimental drug vonsetamig and then had a kidney transplant in a previous study. No new treatment is given here. Researchers will track side effects and how well the transplanted kidney work…